---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-086658"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:14:36.259475+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports 2025 net loss $29.6M; cash $13M; KOURAGE safety review finds no drug toxicity

## Summary
- Net loss $29.6M ($1.97/share) vs $13.7M ($1.22/share) in 2024; R&D expense $15.2M, G&A $7.9M.
- Cash, equivalents & short-term investments $13.0M as of Dec 31, 2025; expected to fund operations into Q4 2026.
- KOURAGE trial in AKI discontinued; internal & external safety review found no evidence of drug-related toxicity.
- Pivotal program design for Auxora in acute pancreatitis expected 1H 2026 following constructive FDA engagement.
- CM5480 for PAH: IND submission anticipated in 2027; preclinical data published in JCI Insight.

## SEC filing metadata
- accession: 0001193125-26-086658
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/0001193125-26-086658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/ck0001534133-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-086658
- JSON: https://secwatch.observer/filing/0001193125-26-086658.json
- Plain text: https://secwatch.observer/filing/0001193125-26-086658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.